In primary human GC tissues, we observed a frequent decrease or loss of GRIM-19 expression which is associated with aggressive clinicopathologic features of patients with GC, suggesting that GRIM-19 may serve as a useful prognosis biomarker in the progression of GC. The gene discussed is NDUFA13; the disease is gastric cancer.